Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of ASTX727 in Participants From Prior Clinical Studies
NCT04093570Phase 2Enrolling by invitation
- Sponsor
- Taiho Oncology
- Start
- Sep 2019
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 2 trial of inqovi in acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), myelodysplastic syndrome (MDS), sponsored by Taiho Oncology. Started Sep 2019; status: enrolling by invitation.
02
Drugs
inqovi
03
Conditions
acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04093570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04093570.